Manoj Kumar Mishra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Manoj Kumar Mishra has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Ajay Kumar Shukla
Institute of Pharmacy, Dr. Ram Manohar Lohia Avadh University, Ayodhya, Uttar Pradesh, India
5 shared publications - Prasoon Pandey
Shambhunath Institute of Pharmacy, Jhalwa, Prayagraj, Uttar Pradesh, 211015, India
5 shared publications - Ritika Singh
Shambhunath Institute of Pharmacy, Jhalwa, Prayagraj, Uttar Pradesh, 211015, India
5 shared publications - Ahsas Goyal
Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India
3 shared publications Anupamaa Tiwari
3 shared publications- Sagar Pamu
Department of Pharmacy Practice, Institute of Pharmacy, Nirma University, Ahmedabad, 382481, Gujarat, India.
3 shared publications
Latest Publications
- 9 September 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (7) , 285
From Liquid to Gel: Multifunctional Stimuli-responsive Polymers for Targeted Oral Drug Delivery
Oral drug delivery is the delivery method of choice, as it is non-invasive and patients will comply with the delivery method, but many contemporary therape
- 9 September 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (7) , 285
From Liquid to Gel: Multifunctional Stimuli-responsive Polymers for Targeted Oral Drug Delivery
Oral drug delivery is the delivery method of choice, as it is non-invasive and patients will comply with the delivery method, but many contemporary therape
- 9 August 2026
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 31 (7) , 1137-1171
Self-assembled ufasomes of unsaturated fatty acids: mechanisms, characterization, and drug delivery potential
Skin is the largest body organ, is a highly discriminatory barrier whose outermost layer is the stratum corneum, composed of keratin filled corneocytes set in a liquid matrix (Prausnitz and Langer ...
- 9 August 2026
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 31 (7) , 1137-1171
Self-assembled ufasomes of unsaturated fatty acids: mechanisms, characterization, and drug delivery potential
Skin is the largest body organ, is a highly discriminatory barrier whose outermost layer is the stratum corneum, composed of keratin filled corneocytes set in a liquid matrix (Prausnitz and Langer ...
- 22 July 2026
- Published by Elsevier in Food and Humanity
- Vol. 7
Modulation of gut microbiota and promotion of gastrointestinal health by fermented millet-based foods
- 22 July 2026
- Published by Elsevier in Food and Humanity
- Vol. 7
Modulation of gut microbiota and promotion of gastrointestinal health by fermented millet-based foods
- 25 June 2026
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 40 (7) , e70991
Battling Parkinson's and Alzheimer's: The Neuroprotective Power of Carnosic Acid
Neurodegenerative disorders have recently emerged as one of the most difficult worldwide health challenges. Neuronal cell injury is a major factor in neurodegenerative diseases. There seems to be rising interest in developing effective neuroprotective drugs from natural sources. Nutraceuticals, or compounds produced from natural sources have shown neuroprotective effects in both in vitro and in vivo models of neuronal cell death and neurodegeneration. Carnosic acid (CA), a natural compound majorly obtained from rosemary and other herbs, has emerged as a promising neuroprotective agent in neurodegenerative diseases, particularly Alzheimer's and Parkinson's. This review covers the latest findings on the methods by which carnosic acid mitigates key pathological features such as oxidative stress, neuroinflammation, apoptosis, and protein aggregation as well as other pathways related to Parkinson's and Alzheimer's disease induction. Furthermore, we describe preclinical and clinical research that demonstrates the ability of carnosic acid to improve cognitive function and motor performance. This study will give a detailed overview of carnosic acid as a possible therapeutic agent, opening the path for future research into viable therapies for Alzheimer's and Parkinson's disorders.
- 25 June 2026
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 40 (7) , e70991
Battling Parkinson's and Alzheimer's: The Neuroprotective Power of Carnosic Acid
Neurodegenerative disorders have recently emerged as one of the most difficult worldwide health challenges. Neuronal cell injury is a major factor in neurodegenerative diseases. There seems to be rising interest in developing effective neuroprotective drugs from natural sources. Nutraceuticals, or compounds produced from natural sources have shown neuroprotective effects in both in vitro and in vivo models of neuronal cell death and neurodegeneration. Carnosic acid (CA), a natural compound majorly obtained from rosemary and other herbs, has emerged as a promising neuroprotective agent in neurodegenerative diseases, particularly Alzheimer's and Parkinson's. This review covers the latest findings on the methods by which carnosic acid mitigates key pathological features such as oxidative stress, neuroinflammation, apoptosis, and protein aggregation as well as other pathways related to Parkinson's and Alzheimer's disease induction. Furthermore, we describe preclinical and clinical research that demonstrates the ability of carnosic acid to improve cognitive function and motor performance. This study will give a detailed overview of carnosic acid as a possible therapeutic agent, opening the path for future research into viable therapies for Alzheimer's and Parkinson's disorders.
- 10 June 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1)
Advances in anti-tau therapeutics for alzheimer’s disease: immunotherapy, gene modulation, and combination approaches
Tau protein abnormalities are more detrimental to neurocognitive function and behaviour than amyloid plaque formation in patients affected by Alzheimer's Disease (AD) - the most common cause of dementia worldwide. Pathologically, tau misfolding, neurofibrillary tangle formation, hyper phosphorylation, and dissociation from microtubules lead to synaptic dysfunction and neuron death. With this understanding, tau is now a major therapeutic target; there is a growing research effort to assess immunotherapy, kinase inhibitors, and tau aggregation inhibitors, and evidence suggests that combination therapies may have synergistic effects. Although there are many challenges remaining, including poor late-stage trial efficacy and limited therapeutic access through the blood-brain barrier, the preliminary results from early preclinical and clinical studies suggest that tau pathology can be reduced and neuronal function improved. Additionally, RNA interference, antisense oligonucleotides, and other gene-based therapies are under investigation. Overall, tau-directed treatments show promise for the treatment of AD, with particular optimism about improvements in delivery systems and combination therapies that will lead to substantial therapeutic benefits and improved quality of life for patients with AD.
- 10 June 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1)
Advances in anti-tau therapeutics for alzheimer’s disease: immunotherapy, gene modulation, and combination approaches
Tau protein abnormalities are more detrimental to neurocognitive function and behaviour than amyloid plaque formation in patients affected by Alzheimer's Disease (AD) - the most common cause of dementia worldwide. Pathologically, tau misfolding, neurofibrillary tangle formation, hyper phosphorylation, and dissociation from microtubules lead to synaptic dysfunction and neuron death. With this understanding, tau is now a major therapeutic target; there is a growing research effort to assess immunotherapy, kinase inhibitors, and tau aggregation inhibitors, and evidence suggests that combination therapies may have synergistic effects. Although there are many challenges remaining, including poor late-stage trial efficacy and limited therapeutic access through the blood-brain barrier, the preliminary results from early preclinical and clinical studies suggest that tau pathology can be reduced and neuronal function improved. Additionally, RNA interference, antisense oligonucleotides, and other gene-based therapies are under investigation. Overall, tau-directed treatments show promise for the treatment of AD, with particular optimism about improvements in delivery systems and combination therapies that will lead to substantial therapeutic benefits and improved quality of life for patients with AD.
- 2 June 2026
- Published by Wiley in Immunology
- Vol. 179 (1) , 37-53
Immunological Reprogramming by Radiation Therapy: Implications for Precision Cancer Treatment
Radiation therapy (RT) is a main part of cancer treatment and is known mostly for its ability to directly kill cancer cells. However, recent studies have shown that RT can have potent immunomodulatory properties, which include both the ability to re‐program the tumour microenvironment (TME) and the activation of systemic anti‐tumour immune responses. It reviews the immune mechanisms involved in the killing of tumours after irradiation, such as immunogenic cell death (ICD), activation of the cGAS–STING (cyclic GMP–AMP synthase–stimulator of interferon genes) pathway, dendritic cell (DC) maturation, priming of cytotoxic T lymphocytes (CTLs), and the abscopal effect, which refers to the regression of non‐irradiated tumours following local irradiation. We also discuss how RT induces immunosuppressive counterforces such as regulatory T cells (Tregs), myeloid‐derived suppressor cells (MDSCs), and programmed death‐ligand 1 (PD‐L1) upregulation. The synergy between RT and immune checkpoint inhibitors (ICIs) such as anti‐programmed cell death protein 1 (anti‐PD‐1), anti‐programmed death‐ligand 1 (anti‐PD‐L1), and anti‐cytotoxic T‐lymphocyte‐associated protein 4 (anti‐CTLA‐4) agents is critically assessed. We also discuss possible clinically relevant enhancement of side effects of immunotherapies by RT. The induction of neo‐antigens and immune activation by chemotherapy (ChX) versus RT is compared/contrasted. Particular focus is paid to dose fractionation approaches, such as stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS), and their differential immunogenic effects. The different tumour types that are most susceptible to radiotherapy‐induced immunologic responses are covered in great detail, particularly malignant melanoma. The field is contextualised with relevant clinical trials, emerging patents, and translational case studies. In this review, we seek to give an integrative framework for how radiation‐induced immune reprogramming can be harnessed in the design of next‐generation precision oncology strategies.
- 2 June 2026
- Published by Wiley in Immunology
- Vol. 179 (1) , 37-53
Immunological Reprogramming by Radiation Therapy: Implications for Precision Cancer Treatment
Radiation therapy (RT) is a main part of cancer treatment and is known mostly for its ability to directly kill cancer cells. However, recent studies have shown that RT can have potent immunomodulatory properties, which include both the ability to re‐program the tumour microenvironment (TME) and the activation of systemic anti‐tumour immune responses. It reviews the immune mechanisms involved in the killing of tumours after irradiation, such as immunogenic cell death (ICD), activation of the cGAS–STING (cyclic GMP–AMP synthase–stimulator of interferon genes) pathway, dendritic cell (DC) maturation, priming of cytotoxic T lymphocytes (CTLs), and the abscopal effect, which refers to the regression of non‐irradiated tumours following local irradiation. We also discuss how RT induces immunosuppressive counterforces such as regulatory T cells (Tregs), myeloid‐derived suppressor cells (MDSCs), and programmed death‐ligand 1 (PD‐L1) upregulation. The synergy between RT and immune checkpoint inhibitors (ICIs) such as anti‐programmed cell death protein 1 (anti‐PD‐1), anti‐programmed death‐ligand 1 (anti‐PD‐L1), and anti‐cytotoxic T‐lymphocyte‐associated protein 4 (anti‐CTLA‐4) agents is critically assessed. We also discuss possible clinically relevant enhancement of side effects of immunotherapies by RT. The induction of neo‐antigens and immune activation by chemotherapy (ChX) versus RT is compared/contrasted. Particular focus is paid to dose fractionation approaches, such as stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS), and their differential immunogenic effects. The different tumour types that are most susceptible to radiotherapy‐induced immunologic responses are covered in great detail, particularly malignant melanoma. The field is contextualised with relevant clinical trials, emerging patents, and translational case studies. In this review, we seek to give an integrative framework for how radiation‐induced immune reprogramming can be harnessed in the design of next‐generation precision oncology strategies.
- 30 May 2026
- Published by Springer Nature in Drug Delivery and Translational Research
Dual-drug nanostructured lipid carriers of spironolactone and 2-deoxy-D-ribose for targeted follicular delivery in androgenetic alopecia
Androgenetic alopecia (AGA) is a multifactorial condition driven by dihydrotestosterone (DHT)-induced follicular miniaturization and reduced perifollicular angiogenesis. Existing treatments such as finasteride, minoxidil, and dutasteride often show limited efficacy and systemic side effects like sexual dysfunction or cardiovascular issues, necessitating targeted approaches. The present study developed dual-drug nanostructured lipid carriers (NLCs) co-delivering spironolactone (SL), an anti-androgen, and 2-deoxy-D-ribose (2dDR), a pro-angiogenic agent, for synergistic follicular regeneration. NLCs were prepared by the hot microemulsion method, incorporating stearic acid as a solid lipid and fenugreek oil as a liquid lipid, with Span 80/Tween 80 surfactants. A Central Composite Design (CCD) was optimised to achieve minimal particle size and optimal zeta potential by varying lipid ratios and surfactant levels. The formulations were characterized by particle size analysis and zeta potential measurements, differential scanning calorimetry (DSC), X-ray diffraction (XRD), Fourier-transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), and in vitro drug release kinetics. Cytotoxicity and dihydrotestosterone (DHT)-protection assays were performed using human dermal papilla cells (hDPCs). Optimized SL-2dDR NLCs exhibited a particle size of 343.03 ± 9.0 nm, a PDI of 27.97 ± 2.84%, and a zeta potential of -20.13 ± 0.40 mV. Entrapment efficiency reached 99.00 ± 0.5% for SL and 98.75 ± 0.7% for 2dDR. DSC and XRD confirmed amorphous drug dispersion, while SEM revealed irregular, porous morphology favorable for follicular adhesion. In vitro release followed Higuchi kinetics for SL (R2 = 0.994) and Hixson-Crowell for 2dDR (R2 = 0.985). MTT assays demonstrated concentration-dependent cytoprotection against DHT-induced cytotoxicity, maintaining 82% cell viability at 50 µg/mL. The dual-drug NLC system represents a promising targeted therapy for AGA, combining anti-androgenic and pro-angiogenic mechanisms while minimizing systemic exposure.
- 30 May 2026
- Published by Springer Nature in Drug Delivery and Translational Research
Dual-drug nanostructured lipid carriers of spironolactone and 2-deoxy-D-ribose for targeted follicular delivery in androgenetic alopecia
Androgenetic alopecia (AGA) is a multifactorial condition driven by dihydrotestosterone (DHT)-induced follicular miniaturization and reduced perifollicular angiogenesis. Existing treatments such as finasteride, minoxidil, and dutasteride often show limited efficacy and systemic side effects like sexual dysfunction or cardiovascular issues, necessitating targeted approaches. The present study developed dual-drug nanostructured lipid carriers (NLCs) co-delivering spironolactone (SL), an anti-androgen, and 2-deoxy-D-ribose (2dDR), a pro-angiogenic agent, for synergistic follicular regeneration. NLCs were prepared by the hot microemulsion method, incorporating stearic acid as a solid lipid and fenugreek oil as a liquid lipid, with Span 80/Tween 80 surfactants. A Central Composite Design (CCD) was optimised to achieve minimal particle size and optimal zeta potential by varying lipid ratios and surfactant levels. The formulations were characterized by particle size analysis and zeta potential measurements, differential scanning calorimetry (DSC), X-ray diffraction (XRD), Fourier-transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), and in vitro drug release kinetics. Cytotoxicity and dihydrotestosterone (DHT)-protection assays were performed using human dermal papilla cells (hDPCs). Optimized SL-2dDR NLCs exhibited a particle size of 343.03 ± 9.0 nm, a PDI of 27.97 ± 2.84%, and a zeta potential of -20.13 ± 0.40 mV. Entrapment efficiency reached 99.00 ± 0.5% for SL and 98.75 ± 0.7% for 2dDR. DSC and XRD confirmed amorphous drug dispersion, while SEM revealed irregular, porous morphology favorable for follicular adhesion. In vitro release followed Higuchi kinetics for SL (R2 = 0.994) and Hixson-Crowell for 2dDR (R2 = 0.985). MTT assays demonstrated concentration-dependent cytoprotection against DHT-induced cytotoxicity, maintaining 82% cell viability at 50 µg/mL. The dual-drug NLC system represents a promising targeted therapy for AGA, combining anti-androgenic and pro-angiogenic mechanisms while minimizing systemic exposure.
- Open Access
- 21 May 2026
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 01_Special (19) , 982
Application of Neurogenomics and Molecular Technologies for Alzheimer's and Parkinson’s Diseases
Neurogenomics is an interdisciplinary field that focuses on studying the genetic fundamentals of neurodegenerative diseases, seeking to understand how genetic variations contribute to the onset, progression, and severity of diseases such as Alzheimer's and Parkinson's diseases. This review aims to investigate and critically assess the evolving roles of neurogenomics and molecular technologies in the understanding, early identification, and treatment advancement for Alzheimer's and Parkinson's diseases. Neurogenomics aims to find specific genetic mutations, polymorphisms, and epigenetic variables to provide new therapeutic targets and potential biomarkers for early diagnosis. Molecular diagnosis plays a pivotal role in identifying genetic risk factors and distinguishing between different neurodegenerative conditions. This article seeks to emphasize recent progress in gene expression profiling, biomarker identification, and transgenic model research, while addressing the therapeutic significance of tools such as PCR, ISH, and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR). The study highlights how the integration of genomic techniques with molecular biomarkers can enhance disease prognosis, patient stratification, and individualized therapy approaches for neurological diseases.
- 21 May 2026
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 01_Special (19) , 982
Open AccessApplication of Neurogenomics and Molecular Technologies for Alzheimer's and Parkinson’s Diseases
Neurogenomics is an interdisciplinary field that focuses on studying the genetic fundamentals of neurodegenerative diseases, seeking to understand how genetic variations contribute to the onset, progression, and severity of diseases such as Alzheimer's and Parkinson's diseases. This review aims to investigate and critically assess the evolving roles of neurogenomics and molecular technologies in the understanding, early identification, and treatment advancement for Alzheimer's and Parkinson's diseases. Neurogenomics aims to find specific genetic mutations, polymorphisms, and epigenetic variables to provide new therapeutic targets and potential biomarkers for early diagnosis. Molecular diagnosis plays a pivotal role in identifying genetic risk factors and distinguishing between different neurodegenerative conditions. This article seeks to emphasize recent progress in gene expression profiling, biomarker identification, and transgenic model research, while addressing the therapeutic significance of tools such as PCR, ISH, and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR). The study highlights how the integration of genomic techniques with molecular biomarkers can enhance disease prognosis, patient stratification, and individualized therapy approaches for neurological diseases.